Where Does PhaseBio Pharmaceuticals Inc. (PHAS) Rank When It Comes To Price-To-Earnings Ratio?

Where Does PhaseBio Pharmaceuticals Inc. (PHAS) Rank When It Comes To Price-To-Earnings Ratio?

(NASDAQ:PHAS) finished Friday with a subtraction of -$0.04 to close at $1.95, a downside of -2.01 percent. An average of 926,460 shares of common stock have been traded in the last five days. There was a fall of -$0.3200 in the past week, and it reached a ...
17 hours ago
from: The Fosters Leader

Continue reading...
Nasdaq, Price–earnings ratio
More about this
- Approximately 1000 Shares Of Arena Pharmaceuticals Inc. (ARNA) Were Bought By This Insider.
He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential. We've set up an alert service to help smart investors take full advantage of the small cap ...
from: The Fosters Leader
- Traders should follow this: GEE Group, Inc. (AMEX:JOB), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)
Liquidity: The stock has a market cap of $50.04M with 92.35M shares outstanding, of which the float was 70.16M shares. Analysts consider this stock active, since it switched Trading volume reached 1,272,061 ...
from: Stocks Equity